Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based...
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl...
Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck CancersMISSISSAUGA, Ontario and HELSINKI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbix...
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...
Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b...
Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase...
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical...
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and...
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025WALTHAM,...
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apneaNEW...
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and...
The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy...
Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers...
NANAIMO, British Columbia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading lifestyle...
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab...
TRUE-See Expands Its AI Clinical Leadership Capabilities with Addition of Dr. Peter Chang as Senior AI AdvisorNEW ORLEANS, Sept. 17,...
Unique technology developed to extend residence time of therapeutic proteins on nasal and other mucosal surfacesAnchoring proteins in place can...
PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company...
Structurally-guided discovery using high-resolution cryo-EM has delivered potent, DCAF16-dependent Targeted Glues™ of SMARCA2, with exquisite selectivity over close homolog, SMARCA4.Rapid,...
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSUHAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) --...